Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Aptevo Therapeutics Inc Product APVO436 Improves the Treatment of Resistant AML and MDS

May 26, 2021 0

Aptevo Therapeutics Inc in the News Aptevo Therapeutics Inc (APVO) has positive results from the Phase …

Prilenia Therapeutics’ Pridopidine Product for Huntington’s and Lou Gehrig’s Diseases Could be Promising

May 25, 2021 0

Prilenia Therapeutics Prilenia Therapeutics is a clinical-stage biotech company. The firm’s leader, Michael Hayden, MD, PhD., …

Recursion Pharmaceuticals: A Step Forward Towards Improving C. Difficile Treatment

May 25, 2021 0

Recursion Pharmaceuticals Product REC-163964 Recursion Pharmaceuticals Inc (RXRX) announced the initiation of an investigational new drug …

Annovis Bio Inc: Very Encouraging Trial Results in Neurodegenerative Diseases

May 21, 2021 0

Annovis Bio Inc and Neurodegenerative Diseases Annovis Bio Inc (ANVS), a clinical-stage drug platform company. This …

Reata Pharmaceuticals: Good News from the FDA Regarding Omaveloxolone for Friedreich’s Ataxia

May 19, 2021 0

Reata Pharmaceuticals Good News Reata Pharmaceuticals (RETA) announced it received a communication from the Division of …

An Important Agreement Between Bristol-Myers Squibb and Agenus

May 18, 2021 0

Bristol-Myers Squibb and Agenus Agreement for AGEN1777 Bristol-Myers Squibb (BMY) and Agenus (

More Vaccines from GlaxoSmithKline: One with Sanofi and Another with CureVac

May 17, 2021 0

Sanofi and GlaxoSmithKline COVID-19 Vaccine Sanofi (SNY) and GlaxoSmithKline (GSK

AstraZeneca and Amgen Product Tezepelumab Seems to Overcome the Resistance of Severe Asthma to Current Treatments

May 14, 2021 0

AstraZeneca and Amgen Announced Results for Tezepelumab for Severe Asthma Tezepelumab Reduced Exacerbations by 77% in …

Compugen: First Quarter Financial Results, Accomplishments and Future Plans

May 13, 2021 0

Compugen Updated Trial Data Updated data from COM701 Phase 1 combination and monotherapy studies to be …

Cassava Sciences Awarded NIH Grant. See Also: Intellia Therapeutics Presentations at the 24th ASGCT Meeting

May 12, 2021 0

Cassava Sciences Awarded NIH Research Grant for Simufilam Cassava Sciences (SAVA) announced that it has been …

Sutro Biopharma: First Quarter Financial Results, Business Highlights and More

May 10, 2021 0

Sutro Biopharma Inc Sutro Biopharma (STRO) is a clinical-stage drug discovery, development and manufacturing company. Its …

ADC Therapeutics: Moving from a Development-Stage Firm to a Revenue-Generating Firm

May 7, 2021 0

ADC Therapeutics First Quarter Financial Results and Business Updates ADC Therapeutics SA (ADCT) is a commercial-stage biotechnology …

Editas Medicine: Business Highlights and Financial Results Reported

May 5, 2021 0

Editas Medicine Reporting Editas Medicine (EDIT) reported business highlights and financial results for the first quarter …

Vir Biotechnology

May 4, 2021 0

Prohost Portfolio PLUS #5 Vir Biotechnology Vir Biotechnology (VIR) combines cutting-edge technologies with immunologic insights to …

Gilead Sciences Conference Call Information. See Also: Compugen Announcements

April 29, 2021 0

Gilead Sciences First-Quarter 2021 Financial Results Conference Call Info Gilead Sciences (GILD) management will host a …

AstraZeneca: Tagrisso Recommended for Marketing Authorization in the EU for Early Stage EGFRm NSCLC

April 27, 2021 0

AstraZeneca: Tagrisso for Adult Patients with Early-Stage EGFRm NSCLC... AstraZeneca (AZN): Tagrisso (osimertinib) has been recommended …

Sanofi and AstraZeneca: Nirsevimab Protects Healthy Pre-Term and Term Infants from Respiratory Syncytial Virus

April 27, 2021 0

Sanofi and AstraZeneca MELODY Trial Results for Nirsevimab In March 2017, Sanofi (SNY) and AstraZeneca (

Vertex and CRISPR Therapeutics: The EMA Granted PRIME Designation to CTX001. Read Also: Cassava Sciences Encouraging News

April 26, 2021 0

Vertex and CRISPR Granted PRIME Designation from the EMA for CTX001 Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics …

Celldex Therapeutics See Also: More of Your Questions Answered

April 26, 2021 0

Prohost Portfolio PLUS #4 Celldex Therapeutics Celldex Therapeutics (CLDX) stock is gaining momentum. On April 12, …

Gilead and Eisai Submitted an Application to Japan’s PMDA for Approval of Filgotinib for UC

April 23, 2021 0

Gilead Sciences and Eisai Pharmaceutical Co Submitted an Application to Japan's PMDA for Filgotinib Galapagos NV …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Aptevo Therapeutics Inc Product APVO436 Improves the Treatment of Resistant AML and MDS

Prilenia Therapeutics’ Pridopidine Product for Huntington’s and Lou Gehrig’s Diseases Could be Promising

Recursion Pharmaceuticals: A Step Forward Towards Improving C. Difficile Treatment

Annovis Bio Inc: Very Encouraging Trial Results in Neurodegenerative Diseases

Reata Pharmaceuticals: Good News from the FDA Regarding Omaveloxolone for Friedreich’s Ataxia

An Important Agreement Between Bristol-Myers Squibb and Agenus

More Vaccines from GlaxoSmithKline: One with Sanofi and Another with CureVac

AstraZeneca and Amgen Product Tezepelumab Seems to Overcome the Resistance of Severe Asthma to Current Treatments

Compugen: First Quarter Financial Results, Accomplishments and Future Plans

Cassava Sciences Awarded NIH Grant. See Also: Intellia Therapeutics Presentations at the 24th ASGCT Meeting

Sutro Biopharma: First Quarter Financial Results, Business Highlights and More

ADC Therapeutics: Moving from a Development-Stage Firm to a Revenue-Generating Firm

Editas Medicine: Business Highlights and Financial Results Reported

Vir Biotechnology

Gilead Sciences Conference Call Information. See Also: Compugen Announcements

AstraZeneca: Tagrisso Recommended for Marketing Authorization in the EU for Early Stage EGFRm NSCLC

Sanofi and AstraZeneca: Nirsevimab Protects Healthy Pre-Term and Term Infants from Respiratory Syncytial Virus

Vertex and CRISPR Therapeutics: The EMA Granted PRIME Designation to CTX001. Read Also: Cassava Sciences Encouraging News

Celldex Therapeutics See Also: More of Your Questions Answered

Gilead and Eisai Submitted an Application to Japan’s PMDA for Approval of Filgotinib for UC